| Literature DB >> 34027097 |
Lily Li-Wen Wang1,2,3, Morgan E Janes1,2,3, Ninad Kumbhojkar1,2, Neha Kapate1,2,3, John R Clegg1,2, Supriya Prakash1,2, Mairead K Heavey4, Zongmin Zhao1,2, Aaron C Anselmo4, Samir Mitragotri1,2.
Abstract
Cell therapies have emerged as a promising therapeutic modality with the potential to treat and even cure a diverse array of diseases. Cell therapies offer unique clinical and therapeutic advantages over conventional small molecules and the growing number of biologics. Particularly, living cells can simultaneously and dynamically perform complex biological functions in ways that conventional drugs cannot; cell therapies have expanded the spectrum of available therapeutic options to include key cellular functions and processes. As such, cell therapies are currently one of the most investigated therapeutic modalities in both preclinical and clinical settings, with many products having been approved and many more under active clinical investigation. Here, we highlight the diversity and key advantages of cell therapies and discuss their current clinical advances. In particular, we review 28 globally approved cell therapy products and their clinical use. We also analyze >1700 current active clinical trials of cell therapies, with an emphasis on discussing their therapeutic applications. Finally, we critically discuss the major biological, manufacturing, and regulatory challenges associated with the clinical translation of cell therapies.Entities:
Keywords: T cell; blood cell; cell; cell therapy; clinical translation; clinical trials; microbes; stem cell
Year: 2021 PMID: 34027097 PMCID: PMC8126820 DOI: 10.1002/btm2.10214
Source DB: PubMed Journal: Bioeng Transl Med ISSN: 2380-6761